CSF2 and congenital rubella syndrome: In addition, anakinra (Giavridis et al., 2018; Norelli et al., 2018) (inhibition of IL-1 binding to IL-1RI), dasatinib (Montero et al., 2011) (inhibition of T cell activation and T cell signal kinase), and lenzilumab (Teachey et al., 2016; Sterner et al., 2019) (GM-CSF antibody) may also be able to control CRS.